Clinical Trial Update: Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating lenalidomide, methotrexate, cytarabine, and rituximab in relapsed aggressive B-cell lymphomas has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Lenalidomide (lenalidomide)
• METHOTREXATE (METHOTREXATE)
• Rituximab (rituximab)

Snippet

Sponsor: University Hospital, Essen | Conditions: B-cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED